Accelerating Breakthroughs in Emerging Technology Business

HONG KONG, Aug. 25, 2026 /PRNewswire/ -- NINGBO JOYSON ELECTRONIC CORP. ("Joyson Electronics" or the "Group", stock codes: 0699.HK / 600699.SH), a world‑leading smart mobility technology solutions provider, announced its interim results for the six‑month period ended 30 June 2026 (the "Reporting Period"). In 1H2026, Joyson Electronics remained committed to its objectives of delivering stable growth and improving profitability, while proactively navigating a challenging operating environment. The company's core automotive components business maintained steady growth and demonstrated resilient profitability.

Through organizational innovation and strategic expansion, Joyson Electronics is leveraging its strengths in automotive R&D and advanced manufacturing to accelerate its presence in emerging technology sectors, including emerging intelligent agent, intelligent computing center and low-altitude aircraft, creating new growth drivers beyond its core automotive business.

Core Business Demonstrates Strong Resilience, with Continued Improvement in Overseas Profitability

During the reporting period, the company generated revenue of approximately RMB 28.1 billion, while net profit attributable to shareholders reached approximately RMB 0.74 billion, representing a year-on-year increase of approximately 4.4%. Net operating cash flow amounted to approximately RMB 1.93 billion, continuing its year-on-year improvement trend.

As the benefits of overseas integration and long-term cost reduction and efficiency enhancement initiatives continued to materialize, gross margin in overseas markets increased by approximately 0.3% year-on-year to around 18.1% in the first half of the year, further strengthening the company's profitability. The Group's overseas gross margin has increased significantly from approximately 9% in the first half of 2022 to the current level, more than doubling and marking a milestone in its overseas integration and cost-optimization initiatives.

Intelligent Technologies Drive Core Business Growth, Supported by a Robust Global Order Backlog

During the reporting period, the company invested approximately RMB 2.28 billion in research and development. To continuously strengthen its core competitiveness, Joyson Electronics has ramped up R&D spending focusing on cutting-edge technologies for intelligent electric vehicles such as intelligent driving, as well as emerging intelligent agents, and server power suppliers. The company also further deepened the integration of intelligent cockpit solutions with large AI models, enhancing the user experience and enabling smarter in-vehicle interactions.

In the first half of the year, the company secured new customer nominations worldwide with an estimated lifecycle order value of approximately RMB 44.9 billion. Leading Chinese automakers and emerging EV manufacturers have become key drivers of new order growth, reinforcing the company's position in the global automotive technology market.

Capitalizing on Opportunities of Overseas Vehicle Intelligence Upgrades and the Global Expansion of Chinese Automakers

Joyson Electronics is among the few Chinese automotive suppliers to have established a truly global footprint, with manufacturing facilities and R&D centers across major automotive markets worldwide. Combining its Chinese heritage with a global operating network, the company is uniquely positioned to capture growth opportunities in both international and domestic markets.

Joyson Electronics has secured a number of production program nominations from leading European, Japanese, and Korean automakers. Meanwhile, as Chinese automakers accelerate their global expansion, the company has continued to win orders for overseas vehicle programs from leading domestic brands and emerging EV manufacturers. Its overseas plants have successfully secured localised business from multiple major Chinese OEMs and are currently supporting mass production. At the same time, the company is actively advancing partnerships with additional Chinese automakers to support their international growth strategies.

Currently, the Company's overseas plants have secured localised overseas business orders from a number of leading mainland automakers and are in continuous mass production. Meanwhile, the Group is also advancing overseas cooperation with more mainland automakers to capture the first-mover advantage of Chinese automakers' global expansion.

Expanding Business Boundaries with the Strategic Transformation of the Energy Management

In recent years, Joyson Electronics has been extending its automotive energy management technologies and expertise into emerging high-end technology applications, driving the strategic evolution of its energy management business from an automotive components supplier to a provider of intelligent energy solutions across a broader range of advanced industries. The company now delivers energy products and integrated solutions for a variety of emerging sectors, including intelligent computing center, satellite, and low-altitude aircraft.

Emerging Intelligent Agent Product Upgrades, Delivering Products to Top Customers

Joyson Electronics continues to advance the iteration and commercialization of products for emerging intelligent agents. In the 1H2026, the company launched a series of new products, including dexterous hands, AI head assemblies, and hybrid solid-liquid energy solutions.

Joyson Electronics has begun delivering high-performance body and material as well as central control units to a leading North American and Chinese customers. The company has also established three dedicated subsidiaries: Telephix, focused on dexterous hands; Hyperplane Technology, focused on embodied AI controllers; and Junebot, focused on integrated energy solutions for emerging intelligent agents.

- End -

About NINGBO JOYSON ELECTRONIC CORP.

Ningbo Joyson Electronic Corp. ("Joyson Electronics", 600699.SH / 00699.HK) is a world-leading intelligent automotive technology solution provider, one of the best component suppliers for the world's leading automobile manufacturers. It is committed to the R&D and manufacture of intelligent cockpit, intelligent driving, E-Mobility and automotive safety, etc. Its headquarter is located in Ningbo, China, which owns the Intelligent Automotive Research Institute, the Advanced Energy Research Institute, the New Energy Research Institute, the Automotive Electronics Division and the Automotive Safety Division, etc. Meanwhile, it has 25 R&D centers and over 60 production bases around the world, covering major automotive markets including Asia, Europe and North America.

In the news release, Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline, issued 21-Aug-2026 by Akeso, Inc. over PR Newswire, we are advised by the company that there are some amendments in the "About AK157D1" section. The complete, corrected release follows:

Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline

HONG KONG, Aug. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its investigational next-generation B7-H3-targeting antibody-drug conjugate (ADC), AK157D1, has received clinical trial clearance from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). The clearance allows initiation of a Phase I study in patients with advanced malignant solid tumors. Development of AK157D1 in combination with Akeso's proprietary bispecific antibodies ivonescimab and cadonilimab is also planned.

AK157D1 is the third next-generation ADC candidate from Akeso to enter clinical development, following AK146D1 (TROP2/Nectin-4 ADC) and AK138D1 (HER3 ADC). The clearance further advances the Company's IO2.0 + ADC2.0 strategy and expands its broad innovative oncology pipeline.

B7-H3 is highly expressed in a broad range of solid tumors, including non-small cell lung cancer, small cell lung cancer, prostate cancer, esophageal cancer, nasopharyngeal carcinoma, colorectal cancer, breast cancer, and glioblastoma, with limited expression in normal tissues. This profile supports its potential as a broad-spectrum antitumor target.

AK157D1 was developed entirely in-house and incorporates a proprietary design. In preclinical studies, it has shown potent antitumor activity together with a favorable safety profile. These attributes may help address certain limitations associated with existing ADCs, including hematologic toxicity and interstitial lung disease, and support its continued development as a potential ADC of choice in both mono or combination therapies.

Akeso is advancing its IO2.0 + ADC2.0 strategy, built on proprietary bispecific and multispecific antibody technology and centered on cornerstone IO2.0 assets including ivonescimab and cadonilimab. Through this approach, the company is elevating treatment standards for major cancers worldwide and building a broad oncology portfolio to create next-generation standard of care.

In the immuno-oncology field, Akeso has two approved bispecific antibodies for cancer treatment. The Company is actively evaluating ivonescimab and cadonilimab in combination with its proprietary next-generation ADC candidates. Increasingly, global partners recognize both ivonescimab and cadonilimab as preferred agents for combination regimens and breakthrough therapy explorations across a wide spectrum of tumor types. In the ADC space, Akeso has built a differentiated pipeline of next-generation candidates, including AK146D1 and AK138D1, which are already in clinical development, and AK157D1 and AK158D1 (a bispecific ADC), which are anticipated to enter the clinic shortly. These agents are designed to address the narrow therapeutic window and safety limitations commonly associated with first-generation ADCs.

About AK157D1

AK157D1 is a novel B7-H3-targeting ADC independently developed by Akeso. Preclinical studies have demonstrated potent antitumor activity and a favorable safety profile.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.

Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

HONG KONG, Aug. 25, 2026 /PRNewswire/ -- Newborn Town Inc., a leading global social entertainment company (Newborn Town or the company, stock code: 09911.HK), released its interim results for the first half of 2026.

For the six months ended 30 June 2026, the company recorded total revenue of US$607 million, representing a year-on-year increase of approximately 37.0%. Profit attributable to equity shareholders of the Company reached approximately US$99 million, up approximately 45.8% year-on-year, while adjusted EBITDA amounted to approximately US$111 million, representing year-on-year growth of 23.6%.

According to the announcement, the first half of 2026 marked a critical phase in the deeper execution of the Company's global strategy. During the period, Newborn Town maintained strong growth momentum, with a more diversified, multi-market growth profile taking shape at an accelerated pace. As its core products gained traction across multiple new markets, AI capabilities continued to deepen, and innovative business delivered steady growth, the Company saw continued improvements in revenue scale, profitability and overall operating quality, further strengthening its long-term growth momentum.

Global Expansion and Deeper AI Integration Drive Continued Growth in Social Networking Business

In the first half of 2026, the company's social networking business maintained robust growth, with revenue reached US$539 million, representing a year-on-year increase of 36.5%. Against the continued expansion of the global social entertainment market, Newborn Town further unlocked the value of its social networking business through its global footprint and the deeper integration of AI across the full business value chain.

In the first half of the year, the company has been deepening its "Product Replication + Market Replication" strategy, making significant progress in its global expansion. Leveraging its deep localization capabilities, Newborn Town further consolidated its leading position in core markets including MENA and Southeast Asia. Meanwhile, its flagship products further strengthened their competitiveness in emerging markets such as Latin America and continued to make inroads into high-potential markets across East Asia, Europe and North America, further broadening the company's global footprint.

The gaming-oriented social networking platform TopTop continued to deepen its presence in high-value markets, with revenue growing by approximately 30% year on year. While further consolidating its position in MENA, TopTop also made progress across a number of new markets. In East Asia, the platform repeatedly ranked among the top 10 free iOS casual games in Japan and South Korea. In Europe and North America, TopTop continued to refine its product in response to local user needs, build market awareness and cultivate local communities, delivering encouraging progress.

The live-streaming platform MICO and voice-based social networking platform YoHo continued to maintain leading positions in their respective segments. MICO consistently ranked among the top-grossing social apps on iOS in markets including Saudi Arabia, the UAE and Thailand, while YoHo remained among the top 10 highest-grossing iOS social apps in core MENA markets such as Oman and the UAE. Both platforms maintained strong competitiveness across established markets while continuing to enhance localized operations and enrich their content ecosystems.

The company's diverse-audience social networking business also maintained steady growth. HeeSay, its global community platform, continued to strengthen its presence in Southeast Asia, consistently ranking among the top 10 highest-grossing iOS social apps across multiple markets in the region. Earlier this year, HeeSay hosted its annual gala in Thailand and launched the interview series 'He So Glam'. Through ongoing enhancements to community engagement and a richer content ecosystem, HeeSay continued to expand its global brand influence.

Innovative Business Posts Strong Growth as AI Drives Short-Drama Expansion

In the first half of the year, the company's innovative business recorded revenue of approximately US$68 million, representing a year-on-year increase of 41.2%. Notably, growth in the AI-powered short drama business provided an additional contribution to the segment's revenue.

According to market research firm Omdia, global short drama revenue is expected to reach US$14 billion by the end of 2026. Playlet, Newborn Town's short-form drama app, is strategically positioned in high-spending markets such as the United States, Japan and South Korea, producing titles at scale that are tailored to local tastes. In the first half, deeper application of AI further expanded content production capacity and creative possibilities, improving per-title launch efficiency by more than 60% and providing strong support for global expansion. According to Diandian Data, Playlet ranked No. 1 among free iOS entertainment apps in Japan in early July.

The company's quality games business also maintained solid momentum, with flagship titles sustaining long-term operations and generating sustained returns. Meanwhile, as the team accumulated further experience across R&D and operations, its ability to develop new titles continued to strengthen. In the first half of the year, three new games made solid progress in commercialization and began to demonstrate potential for further scale.

The social e-commerce business continued to deepen its presence in the health services sector, further strengthening its professional capabilities and competitive barriers. Recently, joint research by Heer Health and Tsinghua University was accepted for presentation at the 26th International AIDS Conference. Meanwhile, Heer Health Internet Hospital was included in the "AIDS Prevention" WeChat Mini Program operated by the National Center for AIDS/STD Control and Prevention under the Chinese Center for Disease Control and Prevention.

AI Drives Efficiency Across the Value Chain as Application Ecosystem Expands

Newborn Town continued to deepen its AI deployment. In the first half, AI gaming community Aippy recorded rapid growth, with global downloads exceeding 4 million to date. Daily active users (DAU) increased by approximately sixfold from the beginning of the year, while user retention remained among the strongest in the industry. The Company also expanded into AI-agent payments with NUSD Pay, broadening the range of AI use cases in its portfolio.

Meanwhile, the Company also continued to invest across the AI ecosystem, backing projects in areas including world models and AI-native game engines, as well as AI interactive games and AI advertising and marketing, further enriching its AI application ecosystem.

In the first half, the Company continued to deepen the use of AI across key areas including product R&D, social recommendation systems, intelligent operations, safety and risk management, and marketing and user acquisition, supporting ongoing business growth.

In marketing and user acquisition, the Company's intelligent creative production platform Cube and intelligent advertising platform Miaomiao worked in close coordination to build an efficient, end-to-end AI-powered workflow — from identifying high-performing creatives and producing ad assets to bid optimization and campaign management — significantly improving advertising efficiency.

On the product operations front, the Company's intelligent data platform Siyu AI continued to enhance its analytical capabilities, reducing processing time for certain complex analytical tasks from days to minutes. Meanwhile, intelligent design platform KIVI continued to expand its design capabilities, further improving the efficiency of producing virtual gifts and UI assets while supporting a broader range of in-app campaigns.

The company also continued to deliver on its commitment to shareholder returns. As of 30 July, Newborn Town had completed three rounds of cancellations of repurchased shares during the year, cancelling a total of approximately 12.87 million shares, with aggregate repurchase consideration exceeding HK$108 million. The cancellations helped lift earnings per share (EPS) and further bolster market confidence alongside the Company's improving profitability.

• Revenue of RMB 11.8 billion grew 18.4% YoY (23.4% YoY in USD)
• IFRS gross profit margin expanded to 46.2% (+350 bps YoY) and adjusted gross profit margin expanded to 48.4% (+280 bps YoY), despite foreign exchange headwinds
• EBITDA grew 3.5% YoY and IFRS net profit rose 5.8% YoY; adjusted EBITDA grew 24.9% and adjusted net profit rose 38.6% YoY
• Earnings per share increased 3.4% YoY; adjusted earnings per share grew 37.3% YoY
• Free cash flow reached RMB 1.5 billion in H1 2026, positive free cash flow for five consecutive years
• Total backlog increased to US$25.1 billion; backlog within 3 years increased to US$5.5 billion, up ~30% YoY
• Record-high 123 new organic integrated projects added in H1 2026 (+43% YoY); WuXi XDC's BioDlink acquisition brought 46 new integrated projects bringing Group's total to 1,064; 70%+ of the new adds and 50%+ of the total projects were complex biologics modalities
• 16 Win-the-Molecule projects in H1 2026, up 78% YoY, including 4 Phase III and 1 commercial; cumulative Win-the-Molecule projects reached 128 since 2018
• 68 INDs filed in H1 2026; expanding IND filing capacity to 300 per year (+50%) by 2027
• 34 PPQs scheduled for 2026 and 30 more for 2027 as of June 2026; 100% PPQ campaign success rate achieved to date
• WuXia™ TrueSite adopted in 70+ projects since launch in October 2025, enabling faster development timelines, higher productivity and lower COGS to support Group's project wins, strengthen Win-the-Molecule competitiveness and enable strong growth of biosimilar programs
• Well-positioned to capture incremental demand from digital advances in drug discovery and next-gen therapeutic platforms

HONG KONG, Aug. 25, 2026 /PRNewswire/ -- WuXi Biologics (Cayman) Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for biologics discovery, development and manufacturing, is pleased to announce its unaudited interim results for the first half of 2026 ("Reporting Period").

• Financial Highlights

Revenue: Revenue increased 18.4% YoY to RMB 11.8 billion (23.4% growth YoY on USD basis), reflecting broad-based growth across project stages and geographies, driven by strong demand for new IND-enabling programs, continued progression of projects through late-stage development and commercial manufacturing.

Gross Profit and Gross Profit Margin: IFRS gross profit increased 28.1% YoY to RMB 5.4 billion, with gross margin of 46.2%. Adjusted gross profit increased 25.6% YoY to RMB 5.7 billion, with adjusted gross margin of 48.4%. Margin expansion, despite foreign exchange headwinds, was primarily driven by continued operating leverage, improved capacity utilization, and ongoing productivity gains through WuXi Biologics Business System (WBS) and digitalization initiatives.

EBITDA and EBITDA Margin: EBITDA grew 3.5% YoY to RMB 4.4 billion with EBITDA margin of 37.1%, while adjusted EBITDA increased 24.9% YoY to RMB 5.4 billion, with adjusted EBITDA margin expanding to 45.6%.

Net Profit and Net Profit Attributable to Owners of the Company: IFRS net profit rose 5.8% YoY to RMB 2.9 billion, while net profit attributable to owners of the company grew 4.3% YoY to RMB 2.4 billion.

Adjusted Net Profit and Adjusted Net Profit Attributable to Owners of the Company: Adjusted net profit increased 38.6% YoY to RMB 3.9 billion, while adjusted net profit attributable to owners of the Company rose 38.4% YoY to RMB 3.3 billion. The difference between IFRS and adjusted net profit growth was primarily driven by the unrealized foreign exchange loss due to USD devaluation in the reporting period, and the investment gains in the prior year baseline, both of which were excluded from the adjusted profit measurement.

Basic Earnings Per Share (EPS): Basic EPS rose 3.4% to RMB 0.60 (June 30, 2025: RMB 0.58), while diluted EPS advanced 5.5% to RMB 0.58 (June 30, 2025: RMB 0.55).

Adjusted Earnings Per Share (Adjusted EPS): Adjusted basic EPS increased 37.3% to RMB 0.81 (June 30, 2025: RMB 0.59), while adjusted diluted EPS increased 39.3% to RMB 0.78 (June 30, 2025: RMB 0.56).

• Business Highlights

Integrated Project Adds

The Group added 169 new integrated projects in H1 2026, including 123 organically added projects (+43% YoY); WuXi XDC's BioDlink acquisition brought 46 new integrated projects, bringing the Group's total to 1,064. 2/3 of the 123 organic additions originated in the U.S. and EU, reflecting continued strong demand from both big pharma and biotech. Now with 78 projects in Phase III and 28 in commercial manufacturing stage, the pipeline continues to provide strong visibility into the future manufacturing revenue growth.

Of the 123 new organic projects, 16 were post-IND wins under the Group's "Win-the-Molecule" (WtM) strategy, including 4 Phase III and 1 commercial project, bringing cumulative WtM projects to 128 since 2018. 70%+ of WtMs in H1 2026 were complex biologics modalities, while 2 were biosimilars.

Research

Research Services continued to make solid progress in H1 2026. As of June 30, 2026, Research Services supported 50+ active programs eligible for milestone payments and sales royalties, providing a growing base of potential high-margin, long-term revenue streams. 50%+ of these programs were sponsored by overseas clients, reflecting the continued globalization of the Group's Research Services business.

Development

The Group supported 68 IND filings in H1 2026 and expects to expand annual filing capacity to 300 INDs by 2027. The filing capacity expansion will be supported by continued investment in development talents and higher per-capita productivity, in response to the strong growth globally.

Bi-/multi-specific antibodies and ADCs accounted for 70%+ of new projects, with their respective pipelines expanding to 221 and 328 projects. These complex biologics modalities continued to drive business growth, contributing 50%+ of Group revenue in H1 2026, up ~30% YoY.

WuXia™ TrueSite, the Group's targeted-integration CHO cell line platform introduced in October 2025, has been adopted in 70+ projects since its launch. The platform enables 6-month DNA-to-IND timelines and achieves average titers of 8+ g/L (up to 12 g/L) for mAbs and 7.5+ g/L (up to 10 g/L) for bi-/multi-specifics, improving productivity, reducing manufacturing scale requirements and lowering COGS. WuXia™ TrueSite is expected to become an increasingly important differentiator for the Group's Win-the-Molecule strategy. Its combination of faster development and higher cell-line productivity is particularly attractive for biosimilar programs, where speed and COGS are important success factors.

Manufacturing

As of June 30, 2026, the Group supported 78 Phase III projects and 28 commercial manufacturing projects. 5 late-stage and commercial projects originated from the Group's "Win-the-Molecule" strategy, including 2 biosimilar projects. The Group has scheduled 34 PPQs in 2026 and another 30 in 2027 and has maintained a 100% PPQ campaign success rate to date.

The Group continued to advance its "Global Dual Sourcing" strategy to support growing commercial demands and strengthen global supply chain resilience, while accelerating manufacturing capacity expansion globally through continued investments and strategic asset acquisitions:

• Shanghai Fengxian, China: MFG17 completed its first GMP campaign with zero deviations. With a current capacity of 9,000L, expandable to 20,000L, the facility supports both clinical and commercial manufacturing. DP15 achieved GMP release in April 2026.
• Chengdu, China: The commercial microbial DS/DP facility achieved structural completion and key equipment delivery. Equipped with a 15,000L fermenter and capacity for up to 110 DS batches annually, the facility is expected to achieve GMP release by the end of 2026.
• Hangzhou, China: The Group recently announced the proposed acquisition of Transcenta's process development & manufacturing site in Hangzhou, China, which is adjacent to its existing Hangzhou operations. The facility is expected to create operational synergies and enable flexible capacity expansion in response to the growing client demands.
• U.S.: Construction of MFG11 in Worcester, Massachusetts, with 36,000L (6 x 6,000L) of commercial manufacturing capacity, is progressing as planned. MFG18, in Cranbury, New Jersey, is being upgraded from a clinical manufacturing facility to have commercial manufacturing capabilities with 13,000L+ of total capacity, and has initiated its first PPQ campaign in the 1H of 2026.
• Singapore: The DP facility reached topping out and is expected to provide approximately 100 million units of annual pre-filled syringe and vial capacity upon commencement of operations in 2027. The ongoing design of the 120,000L modular DS facility targets GMP readiness in 2029.
• Ireland: Year-to-date, the Ireland site has secured three new large-scale manufacturing projects and has commenced tech-transfer.

• Business Portfolio Optimization

In July, 2026, the Group entered into an agreement to sell its 51.1% equity interest in BestChrom, a non-wholly owned subsidiary principally engaged in biologics purification media and chromatography columns, to an independent third party for an undisclosed amount. The transaction is expected to close in December 2026, subject to customary closing conditions, after which BestChrom will cease to be a consolidated subsidiary of the Group.

• Backlog

As of June 30, 2026, total backlog reached US$ 25.1 billion, including US$ 12.6 billion service backlog and US$ 12.4 billion potential milestone payments. Backlog within 3 years reached US$ 5.5 billion, up~30% YoY, providing strong revenue visibility over the near term.

• Quality

Since 2017, the Group has completed 49 regulatory inspections by global health authorities, including 23 by the U.S. FDA and EU EMA, with no critical findings or data integrity observations. As of June 30, 2026, the Group had obtained 166 facility license approvals across its global network and operated 15 GMP-certified manufacturing facilities, demonstrating its established global regulatory and quality capabilities.

• Talent

As of June 30, 2026, the Group employed 14,705 people, including 5,180 scientists, with a key talent retention rate of 98.7%. To support continued business growth, the Group plans to further expand its workforce in H2 2026.

• WBS (WuXi Biologics Business System) and Digitalization

WBS continued to drive operational excellence and productivity improvements across the organization. During the Reporting Period, the Group completed 55 Kaizen projects, contributing approximately 150 bps to gross margin improvement through enhanced productivity, cost optimization and process standardization.

The Group also continued to advance its digital manufacturing capabilities, with PatroLab™ enhancing process development, manufacturing efficiency and operational excellence through integrated data and advanced analytics.

• Sustainability

Sustainability remains integral to the Group's long-term strategy. During the Reporting Period, the Group continued to be recognized by leading global ESG rating agencies for its sustainability performance.

• Management Comment

Dr. Chris Chen, CEO of WuXi Biologics, stated, "In H1 2026, WuXi Biologics delivered strong profitable growth, with revenue increasing 23.4% YoY in USD and adjusted gross margin expanding 280 bps to 48.4%, despite foreign exchange headwinds. Broad-based demand, continued operating leverage and productivity gains supported this performance. We added a record-high 123 organic integrated projects, up 43% YoY, while complex biologics accounted for 70%+ of new projects, further upgrading our pipeline mix.

Our technology differentiation is also translating increasingly into commercial competitiveness. WuXia™ TrueSite has been adopted in 70+ projects since launch, supporting faster development and higher cell-line productivity. We expect WuXia™ TrueSite to strengthen both our Follow-the-Molecule and Win-the-Molecule competitiveness, while its speed and potential cost advantages are particularly attractive for biosimilar programs. We're well-positioned to capture incremental demand from digital advances in drug discovery and next-gen therapeutic platforms.

Visibility into future manufacturing growth continues to strengthen, supported by four distinct pillars: progression of our Follow-the-Molecule pipeline toward additional commercial approvals; continued Win-the-Molecule conversion; emerging biosimilar opportunities; and higher value capture through our integrated One DP platform. Looking ahead, we will continue to expand capacity and optimize our business portfolio in a demand-driven and disciplined manner, while investing in differentiated technologies and our global network to support sustained growth and long-term value creation for clients and shareholders."

Dr. Ge Li, Chairman of WuXi Biologics, stated, "H1 2026 reinforced the strength of WuXi Biologics' integrated CRDMO platform and the long-term value of our continued investments in technology, quality and global capabilities. As biologics innovations continue to advance toward increasingly complex modalities, we remain committed to enabling our global partners through differentiated technologies, proven quality and reliable execution. Guided by our vision that 'every biologic can be made,' we will continue to invest for the long term, expand the capabilities of our global platforms and create long-term value for clients, shareholders and patients worldwide."

• Key Financial Ratios

(For the Six Months Ended June 30)

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)
*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Investor: [email protected]
Media: [email protected]

Globalization Accelerates Value Realization of Innovative Drugs

SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company recorded revenue of RMB 20.442 billion, a year-on-year increase of 4.75%, or 7.17% at constant exchange rates. Profit attributable to shareholders of the listed company, net of non-recurring gains and losses, stood at RMB 1.144 billion, up 19.09% year-on-year. Profit growth outpaced revenue growth, reflecting sustained improvement in earnings quality. Net cash generated from operating activities reached RMB 2.424 billion, rising 13.59% year-on-year.

Innovation and globalization stand as the dual core engines driving business performance. Revenue from Innovative Drugs hit RMB 4.911 billion, representing a 13.84% year-on-year increase and accounting for 33.21% of pharmaceutical segment revenue, 2.17 percentage points higher than the same period last year. Business revenue from regions outside Chinese mainland and other countries totaled RMB 6.379 billion, growing 16.45% year-on-year and making up 31.21% of total revenue, a year-on-year uplift of 3.14 percentage points. The Group's revenue mix continues to improve.

Focusing on Core Therapeutic Areas and Accelerating Clinical Translation of Innovative Drugs

Guided by clinical-value-driven innovation, Fosun Pharma prioritises three core therapeutic areas: oncology, immunology and inflammation, and neurodegenerative diseases. It also expands into CVRM (cardiovascular, renal and metabolic), anti-infectives, rare diseases and other segments. Leveraging an open-innovation framework that combines in-house R&D, two-way licensing and fund-incubation models, the Company accelerates clinical translation and pushes forward its innovation-led transformation.

In 1H2026, Fosun Pharma's total R&D investment amounted to RMB 3.247 billion, up 25.66% year-on-year. Among this, R&D investment related to Innovative Drugs accounted for 81.61% of total R&D investment, primarily directed towards pipelines such as HLX43, HLX22, GR1803, FXR0906, as well as next-generation small molecule drugs, radiopharmaceuticals, and other cutting-edge technology platforms.

During the reporting period, Fosun Pharma's Innovative Drugs entered a period of intensive approvals and value realization, with a total of 20 indications of 7 Innovative Drugs were approved for launch both domestically and overseas. In solid tumor areas including lung cancer, breast cancer, and gastrointestinal tumors, the Company has established differentiated competitive advantages through multi-product synergy and global commercialization. Han Li Kang (Rituximab), Han Qu You (trastuzumab), and Akynzeo® continue to maintain leading positions in their respective market segments, consistently contributing stable cash flow.

During H1 2026, Han Si Zhuang (Serplulimab) gained approval in China for the perioperative treatment of gastric cancer, filling a global unmet clinical need. In the EU, it obtained three additional first-line approvals for squamous non-small-cell lung cancer, esophageal squamous-cell carcinoma and non-squamous non-small-cell lung cancer. To date, serplulimab has been launched in approximately 50 countries and regions worldwide and is reimbursed under national health-insurance or public-reimbursement schemes in 12 markets including the United Kingdom, Germany, Italy, Spain and Sweden. Han Bei You (Pertuzumab) received successive marketing approvals in the EU and China. It works in synergy with breast-cancer portfolio assets including Han Qu You, Han Nai Jia and Fu Tuo Ning to drive commercial uptake. Fu Mai Ning (luvometinib tablets) secured a new indication for pediatric and adolescent patients aged two years and older with relapsed/refractory Langerhans-cell histiocytosis (LCH) following systemic therapy, addressing an unmet clinical need in China.

With regulatory applications accepted for multiple innovative drugs and international multi-center clinical trials for key pipelines moving forward efficiently, Fosun Pharma continues to fuel its long-term commercial growth.
- The NDA for SAF-189 (foritinib succinate capsules), an ALK inhibitor for non-small-cell lung cancer, has been accepted by the NMPA.
- The NDA of Fu Mai Ning for adult patients with symptomatic, inoperable plexiform neurofibromas associated with neurofibromatosis type 1 (NF1) has been accepted and granted priority review by the NMPA.
- The NDA for Velinotamig (GR1803), a BCMA × CD3 bispecific antibody for multiple myeloma, has been accepted.

Lead pipeline candidates HLX43 and HLX22 are progressing in international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical efficacy featuring high potency and favorable safety profiles across multiple solid tumors types including non-small-cell lung cancer.

In the immunology and inflammation field, the Company strengthened its in-house R&D while continuously enriching its pipeline through BD collaborations, obtaining the rights to develop, manufacture, and commercialize roconkibart (anti-IL-17A monoclonal antibody) in Chinese mainland, Hong Kong SAR, Macau SAR, and Taiwan region. The complement inhibitor FXS6837 for the treatment of IgA nephropathy and other glomerular diseases associated with complement dysregulation initiated Phase 2b clinical trials in Chinese mainland. The DPP1 inhibitor FXS7553 is in Phase 2 clinical stage in Chinese mainland for two indications: non-cystic fibrosis bronchiectasis and COPD.

In the neurodegenerative diseases field, the integrated diagnosis and treatment layout continues to strengthen. The post-marketing confirmatory clinical trial for Sodium Oligomannate Capsules in Chinese mainland is progressing steadily; as of July 31, 2026, cumulative enrollment exceeded 1,000 cases, reaching over 50% of the planned enrollment target. HT001, an investigational drug for Parkinson's disease, has initiated Phase 1 clinical trials in Australia. Parallel work is underway on the clinical deployment of magnetic-resonance-guided focused-ultrasound therapy and the R&D of companion diagnostic reagents.

Rooted in evidence-based medicine, Fosun Pharma presented three oral abstracts at the 2026 ASCO Annual Meeting, including the Phase 3 study of Fu Mai Ning in adult NF1 patients, the Phase 3 study of serplulimab injection in the perioperative setting for gastric cancer, and the clinical study of HLX43 in non-small cell lung cancer. 10 studies were selected for poster presentations at the 2026 ASCO Annual Meeting, including data from two Phase 3 studies of Fu Tuo Ning and a study of HLX43 in nasopharyngeal carcinoma. The Company continues to deliver high-quality clinical outcomes in top-tier global journals such as The Lancet and Nature Medicine, as well as at global industry academic conferences, providing solid academic support for international registration and commercial expansion of its products.

Deep Globalization: Global Capabilities Accelerate Value Delivery of Innovation

Among China's early-movers in global pharmaceutical expansion, Fosun Pharma is evolving from mere product exports toward system-level global deployment. It strengthens cross-border capabilities across R&D, regulatory affairs, manufacturing and commercialization to maximize the global value of its innovative assets.

In terms of out-licensing, Shanghai Henlius, a subsidiary of Fosun Pharma, has entered strategic partnerships with Eisai and Abbott for serplulimab. Eisai obtains development, manufacturing and exclusive commercialization rights for Japan and agreed territories. Abbott receives exclusive commercial-license rights covering 42 countries and regions across Asia, the Middle East, Africa and Eastern Europe. These collaborations accelerate global roll-out of home-grown innovations for patients worldwide.

In terms of in-licensing, Fosun Pharma entered into a global exclusive option agreement with AriBio for AR1001, an investigational drug for Alzheimer's disease. Building on the existing rights in China and Southeast Asia, Fosun Pharma is entitled to further expand its right to global core markets including the US, Europe, and Japan, with the Company serving as the marketing authorization holder for the product in the corresponding territories. The international multi-center Phase 3 clinical trial of AR1001 for the treatment of early Alzheimer's disease has completed the last patient's last visit, with top-line results to be announced within 2026.

Drawing on years of global GMP-compliant manufacturing experience, Fosun Pharma presses ahead with its internationalization drive. Its biotech manufacturing site supplies products routinely to global markets including China, Europe, Canada, Latin America, Southeast Asia and India. As of period-end, installed biologic capacity totaled 84,000 liters, of which 48,000 liters are commercially operational.

Fosun Pharma's subsidiary Gland Pharma, as the first injectable manufacturer in India to receive U.S. FDA approval, possesses one-stop development and manufacturing capabilities for complex dosage forms including vials, lyophilized products, ampoules, and pre-filled syringes. Gland Pharma recently entered into a strategic supply agreement with a global leading pharmaceutical company for 55 SKUs of sterile injectable, further validating its technological expertise and customer stickiness in the high-barrier complex formulation segment. This platform also provides Fosun Pharma with a unique strategic resource for its globalization layout, creating a differentiated competitive advantage in the process of going global.

Bolstered by its innovation and globalization strengths, Fosun Pharma keeps elevating its industry standing and has achieved an MSCI ESG rating upgrade to AAA^[1]. Domestically, it has ranked among the top 10 of MIIT's China Top 100 Pharmaceutical Enterprises for eight consecutive years. Globally, its innovative-pipeline scale places it within the world's top tier, ranking top 20 in Citeline's Global Top 25 Pipeline Scale Pharmaceutical Companies.

"Amidst challenging industry dynamics, Fosun Pharma responded to external uncertainties with strategic focus, achieving steady revenue growth." Chen Yuqing, Chairman of Fosun Pharma, said, "We stay firmly committed to innovation and globalization. Concentrating on oncology, immuno-inflammation and neurodegenerative diseases, we leverage our global footprint and two-way BD synergies to build stronger commercial capabilities. Amid global-expansion opportunities for China's innovative drugs, we take a long-term view and advance resolutely toward high-quality development."

- END -

About Fosun Pharma

Founded in 1994, Fosun Pharma (stock code: 600196.SH; 02196.HK) is an innovation-driven global pharmaceutical and healthcare group. With the mission of Better Health for Families Worldwide, we focus on developing innovative medicines, medical technologies and diagnostics as well as delivering healthcare services. Through our business partner Sinopharm Group, we have also established pharmaceutical distribution network, built a comprehensive pharmaceutical and healthcare ecosystem.

Fosun Pharma is dedicated to innovation and globalization. The company has established a global R&D innovation system targeting at unmet medical needs. Our strategic focus is on key therapeutic areas including oncology, immunology and inflammation, neurodegenerative diseases, and selected cardiometabolic diseases and rare diseases. This approach enables the development of high valued competitive pipelines and comprehensive healthcare solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small nucleic acids. These efforts have strengthened our early-stage innovative portfolios and accelerated the transformation of scientific discoveries to drug development. Our innovative products are now available in more than 90 countries and regions worldwide, including major markets across China, the United States, Europe, Africa, India and Southeast Asia.

Looking ahead, guided by the strategy of "Innovation Driven, Deep Globalization, and AI Embracement", Fosun Pharma remains committed to its core values: Care for life, Continuous innovation, Pursuit of excellence and Sustainable partnership. We strive to become a leading global healthcare innovation integrator, ensuring that the benefits of medical innovation reach more patients worldwide, and contribute to safeguarding human health.

For more information about the Group, please visit the company website: https://www.fosunpharma.com/en/ 

Transforming from Regional Leader to Global Premier:

A Clear Strategic Path for Growth and Globalization

SAN FRANCISCO and SUZHOU, China, Aug. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, announces its 2026 interim results and 2030 strategic vision.

Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "Looking back over the past fifteen years, Innovent has completed two key transformations: from 2016 to 2020, we transformed from an R&D-driven biotech company into a biopharmaceutical company with full-value-chain capabilities spanning R&D, manufacturing, and commercialization; from 2021 to 2025, we progressed from a long-term investment phase into a biopharmaceutical company that achieved revenue over RMB 10 billion and full-scale profitability. 2026 marks Innovent's best strategic window to date, and it is against this backdrop that we have set forth our new strategic goals for 2030. We have both the resolve and the confidence to drive our third critical transformation: evolving from a regional leading biopharmaceutical company into a global premier biopharma with global business operational capabilities.

In the first half of 2026, Innovent delivered strong growth in both revenue and profit, further reinforcing our leading position in China's biopharmaceutical industry and highlighting our scarce value in both certainty and growth potential. At the same time, over the past ten months, we have reached multiple strategic collaborations with global multinational pharmaceutical leaders including Takeda, Eli Lilly, and Pfizer, while also partnering with biotechs such as Ollin and Spero to advance the global development of our differentiated pipeline. Our partnered pipeline now spans more than 20 assets, including 5 co-development and co-commercialization ("Co-Co") programs, with an aggregate deal value reaching USD 34 billion, representing more than 30% of the total out-licensing value among Chinese pharmaceutical companies over the same period¹. Innovent stands at the most favorable strategic window in its development. We will continue to pursue high-quality growth in revenue and profit, guided by clear strategy and disciplined execution — strengthening and amplifying our 'dual-engine' advantage across oncology and general biomedicine, accelerating our global expansion, and advancing toward our 2030 strategic goals, so as to continue creating long-term value for our shareholders and society."

 A Visible Growth Path: Scale and Profitability Advancing in Parallel

In the first half of 2026, Innovent reached RMB 8.6 billion in total revenue, representing 45% year-over-year growth, while product revenue reached RMB 8.2 billion, up 57% year over year. Building on the RMB 10 billion-plus revenue scale, Innovent maintained strong growth momentum, with its dual-engine strategy of oncology and general biomedicine continuing to deliver.

Rapid revenue growth, coupled with continued improvements in operational efficiency, further drove improvements in profitability. IFRS net profit for the first half of the year was approximately RMB 1.3 billion, representing approximately 50% year-over-year growth, while Non-IFRS net profit reached RMB 1.7 billion, up 41% year over year. Innovent has entered a new stage characterized by simultaneous expansion in scale and improvement in earnings quality, setting a new paradigm for high-quality growth among biopharmaceutical companies.

As of July 31, 2026, Innovent held RMB 30.2 billion in cash reserves, equivalent to approximately US$4.5 billion. In addition, we continued to generate positive cash flow, providing a strong financial foundation for long-term growth.

Vision 2030: From China Leader to Global Premier Biopharma

Building on high-quality growth and systematic portfolio development, the Company has underpinned its 2030 development goals.

• Revenue Scale: By 2030, we target to achieve total revenue of RMB 35–40 billion, largely driven by organic expansion from the existing business and pipeline.
• Sustainable Profitability: By 2030, we aim to benchmark our profit margin to top-tier pharmaceutical companies, through continued revenue expansion and efficiency improvements.
• Global Innovation: By 2030, we aim to advance at least five molecules into global MRCT Phase 3 development, achieve product launches in key markets, i.e. U.S. and Europe with international revenue emerging.
• Globalization: building global infrastructure and business operating capabilities, truly transforming into a global premier biopharmaceutical company.

From "Product-led Growth" to "Portfolio-Driven Growth," with Dual Growth Engines Unleashing New Momentum

China's Leading Oncology Franchise: Strengthening Core Oncology Leadership While Expanding Strategically into Key Growth Areas

In oncology, Innovent has established a strong product portfolio and brand presence across core indications including lung cancer, gastrointestinal cancers and hematological malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2^α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive advantages across multiple strategic areas.

Meanwhile, through its collaboration with Lilly on Verzenio® (abemaciclib) in breast cancer, we have strategically gained an important entry point into this major high-incidence tumor type. This asset lays the foundation for upcoming in-house pipeline programs such as IBI354(HER2 ADC) and IBI3014(PD-L1/TROP2 ADC), and paves the way for a more systematic presence in breast cancer.

General Biomedicine Franchise Emerged as a New Growth Engine

In general biomedicine, Innovent has established a clear framework across four major chronic disease areas—metabolic, cardiovascular, ophthalmology and autoimmune—and this franchise has become another core pillar of Innovent.

SYCUME® (Teprotumumab, IGF-1R antibody), China's first innovative therapy for thyroid eye disease in 70 years; Mazdutide, the world's first and only approved GCG/GLP-1 dual-receptor agonist for obesity and type 2 diabetes; and SINTBILO® (tafolecimab injection), the first China-domestic PCSK9 inhibitor included in the NRDL—all exhibited robust performance. PECONDLE® (picankibart injection, IL-23p19 antibody), the anchor asset in autoimmune diseases, was also approved at the end of 2025.

At the same time, our next‑generation metabolic and obesity pipeline – including IBI3032 (once‑daily oral GLP‑1), IBI3042 (once‑weekly oral GLP‑1), IBI3040 (Amylin), IBI3046 (INHBE siRNA) and IBI3030 (monthly PCSK9‑GGG) – provides deep, long‑term growth reserves in global obesity and metabolic disease. In cardiovascular & metabolism, autoimmune and ophthalmology, we are following a "flagship products life cycle management + next‑generation innovation" strategy to build focused product clusters and durable competitive positions in each area.

Three Late-Stage Global Assets Unlocking More Than US$60 Billion Total Addressable Market (TAM), and 20+ Partnered Programs Accelerating Global Innovation

Innovent is advancing global development of its core assets through multiple collaboration models. Three key assets have entered, or are about to enter, global multi-regional Phase 3 trials, with a combined addressable market estimated at over US$60 billion, and are expected to be major value drivers in the coming years:

IBI363 (PD-1/IL-2^α-biased, Takeda R&D Code: TAK-928): Next-gen IO cornerstone, potential TAM over US$40 billion for first wave of indications, global co-development with Takeda

• A global multi-regional Phase 3 study (MarsLight-11) in IO-resistant squamous non-small cell lung cancer (NSCLC) is ongoing, and with expansion into IO-resistant non-squamous NSCLC in preparation.
• A pivotal Phase 2 study of IBI363 in melanoma in China is expected to read out in the second half of 2026, potentially supporting the first NDA submission for IBI363.
• IBI363 has demonstrated preliminary positive PoC results in first-line NSCLC. PoC studies in first-line NSCLC and first-line colorectal cancer are ongoing, with additional PoC studies being advanced across other tumor types, further supporting its potential as a next-generation IO backbone therapy.

Arcotatug Tavetecan (CLDN18.2 ADC, Innovent/Takeda R&D Code: IBI343/TAK-921): Globally First NDA stage Next-Generation Fc-Silenced CLDN18.2 ADC, potential TAM over US$8 billion

• The China-Japan multicenter Phase 3 study completed its first interim analysis and achieved primary endpoint. The NDA submission has been accepted by NMPA for the treatment of CLDN18.2-positive advanced gastric cancer in later-line settings.
• A Phase 3 study in first-line pancreatic cancer is planned to initiate in China.
• International multicenter Phase 1 and PoC studies in first-line pancreatic cancer and first-line gastric cancer are ongoing.

IBI324 (VEGF/ANG2, Ollin R&D Code: OLN324): Potential best-in-disease retinal therapy, potential TAM US$15 billion

• Our partner Ollin Biosciences reported positive results from the Phase 1b JADE head-to-head study against faricimab in nAMD and DME patients in the U.S.
• Ollin plans to initiate global multi-regional Phase 3 studies in DME and nAMD in the second half of 2026, and through collaboration with Innovent, to conduct patient enrollment in China and South Korea.

Diversified Partnerships to Accelerate Global Innovation

• Over the past 10 months, Innovent has entered into strategic multi-product collaborations with global multi-national pharmaceutical companies including Takeda, Lilly and Pfizer, while partnering with biotech companies such as Ollin and Spero to rapidly validate differentiated pipeline programs in selected disease areas. The aggregate deal value reaching US$34 billion, covering more than 20 pipeline programs, among which five are "Co-Co" assets.
• Leveraging diversified partnership models, the Company will progressively build overseas R&D and commercialization capabilities and evolve into a truly world-class biopharmaceutical company with global business operating capabilities.

High-Quality Manufacturing Standards

• Innovent operates advanced manufacturing facilities built to international standards and our Suzhou manufacturing site has recently undergone and successfully passed a Good Manufacturing Practice (GMP) inspection conducted by the European Medicines Agency (EMA), and has obtained the corresponding GMP certificate.
• Total operational capacity of 140,000 liters, accounting for 20% of China's total biologic manufacturing capacity. Suzhou site houses 60,000 liters of antibody capacity and ADC commercial lines; Hangzhou site has 80,000 liters of antibody capacity, supporting global supply and CDMO services.

Sustainable Development and ESG Commitment

• 9,000 employees worldwide, with global R&D centers in San Francisco Bay Area, Shanghai and Suzhou.
• Over 3,000 new cancer patients initiate Innovent therapies daily; more than 10 million patients have benefited to date.
• Maintained MSCI ESG AAA rating, leading China's biopharmaceutical industry.
• First innovative biopharma constituent of the Hang Seng Index ("blue-chip" status).
• Launched community health initiatives including the MV 'Weight Management Made Easy' and documentary 'Down in Weight, Up in Life' to promote science-based healthy weight management.
• Published patient education materials on thyroid eye disease and weight management to enhance public health awareness.
• Implemented multiple patient assistance programs, benefiting over 200,000 patients with drug donations valued at over RMB 4 billion.
• Received honors including "Healthcare Public Welfare Pioneer" and "China Public Welfare Enterprise".
• Created over 2,700 jobs for new graduates.
• Cumulative taxes and contributions exceeding RMB 9 billion.

Note:

1. Data source: Next Pharma database.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset in NMPA NDA review, 5 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Lilly, Takeda, Pfizer, Roche, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1) Innovent does not recommend the use of any unapproved drug (s)/indication (s).
2) Ramucirumab (Cyramza) and Selpercatinib (Retsevmo), Pirtobrutinib (Jaypirca) and abemaciclib (Verzenios) were developed by Eli Lilly and Company.
Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements of Innovent Biologics

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent's competitive environment and political, economic, legal and social conditions.

TAGUIG CITY, Philippines, Aug. 25, 2026 /PRNewswire/ -- Yadea Philippines and J&T Express have announced a strategic partnership to accelerate the adoption of electric vehicles in the local logistics sector. Manila will serve as the pilot with 1,000 units rolling out initially, followed by nationwide expansion.

As the global No.1 electric two-wheeler brand for nine consecutive years, Yadea operates over 70 branded sales and service centers, with flagship models like EPOC and CL8. Partnering with J&T Express, a leading Philippine courier, will accelerate Yadea's entry into the local logistics market. Together, they aim to optimize logistics and drive a greener, low-carbon future for express delivery, reflecting the companies' shared commitment to sustainable urban mobility and environmental stewardship.

YADEA ST13 is an electric delivery tricycle designed for high-frequency, short-distance commercial delivery scenarios. It integrates energy-efficient transport systems purpose-built for high-frequency urban dispatch. The unit features a weight-reducing mesh cargo box that directly optimizes battery range, paired with premium A+ grade puncture-resistant steel-wire tires designed for continuous delivery operational capability.

Yadea General Manager of the Philippines Wang Chun stated, "This cooperation reflects a deep synergy between product capability and logistics networks, representing a practical response to the country's demand for green transportation. We hope our locally tailored electric vehicles allow delivery personnel to ride with greater peace of mind and operate more efficiently, injecting tangible momentum into low-carbon urban logistics."

J&T Express Philippines National Capital Region Key Account Manager Mary Andaya stated, "Through this collaboration, we are actively integrating electric vehicle solutions into our last-mile operations. This initiative optimizes our daily workflow while aligning with our shared direction of collaborating on the large-scale adoption of electric tricycles for deliveries to enhance delivery efficiency within the local logistics sector."

About YADEA

YADEA is a leading electric mobility brand and has ranked No.1 globally in electric two-wheeler sales for nine consecutive years. Driven by innovation, YADEA provides electric two-wheelers, electric tricycles and other mobility solutions to users around the world through its integrated capabilities in R&D, manufacturing, products channels and services.

About J&T Express Philippines

J&T Express Philippines, a nationwide logistics provider established in 2019, offers express delivery services via land, air, and sea. The company operates automated distribution centers and maintains extensive trucks and delivery services that run 24/7, ensuring that packages are safely delivered across the Philippines.

Contact:
[email protected]

NVIDIA Corporation (NVDA.US) announced that its Groq 3 LPX chips have entered full-scale production.

Senior Director Dion Harris said the Groq chips will be deployed alongside the Vera CPU and Rubin GPU at cloud service provider Nebius, with launch scheduled for later this year.

NVIDIA is accelerating production and customer supply of Groq chips, reflecting the growing importance of low-latency inference technology.

The technology helps AI agents improve response speed in applications such as coding and reduces user waiting time. NVIDIA noted that cloud companies can charge higher fees for related token services.

NVIDIA acquired Groq assets for USD20 billion in December 2025, marking the company's largest-ever acquisition. Groq chips are manufactured by Samsung, while TSMC (TSM.US) produces NVIDIA's GPUs.
~

AASTOCKS Financial News
Website: www.aastocks.com

• Group total revenue increased to RMB 3,701.4 million, representing 37.0% period-over-period growth on an AER^[1] basis (41.5% growth on a CER^[2] basis)
• Gross profit grew by 40.6% period-over-period, reaching RMB 1,371.3 million. Gross profit margin was 37.0%, a 0.9 percentage points increase compared to 2025 1H
• Adjusted net profit attributable to owners of the Company increased by 37.4% period-over-period, reaching RMB 1,027.3 million. The margin of adjusted net profit attributable to owners of the Company remained stable at 27.8%, a 0.1 percentage increase compared to 2025 1H
• The total global customer base expanded to over 810 companies, and 15 out of the TOP 20 global pharmaceutical companies have partnered with us
• The total number of iCMC projects reached 328, with 51 newly signed iCMC projects
• The commercial and PPQ pipeline: 2 commercial projects; 21 PPQ projects in total, with 2 PPQ projects newly signed in 2026 1H
• The service backlog grew to approximately US$2.0 billion, a solid 50.4% increase period-over-period. Including the upcoming milestone fee, total backlog reached approximately US$2.2 billion, up 62.2% period-over-period

SHANGHAI, Aug. 24, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. (the "WuXi XDC" or the "Group", stock code: 2268.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) focused on the bioconjugate market, is pleased to announce its interim results for the six months ended June 30, 2026 (the "Reporting Period").

CEO Comment

Dr. Jimmy Li, CEO of WuXi XDC, stated, "Our strong first-half 2026 performance reflects the continued execution of our long-term strategy and increasing global demand for integrated bioconjugate CRDMO services. During the period, we further strengthened our capabilities through the successful integration of BioDlink, continued expansion of our global manufacturing network, and advancement of our proprietary technology platforms. Looking ahead, we remain committed to empowering customers through our 'Enable, Follow and Win the Molecule' strategy and are well positioned to capture the significant opportunities emerging across the broader XDC market."

Financial Highlights for Interim Results of 2026

Revenue

• The Group's revenue increased to RMB 3,701.4 million for the six months ended June 30, 2026, representing 37.0% period-over-period growth on an AER basis (41.5% on a CER basis).  
• This increase was primarily attributable to (i) the growth in the number of customers and projects, driven by continued active development of the global ADC and broader bioconjugates market, (ii) the increasing market share through the Group's established position as a leading ADC CRDMO service provider in that market, and (iii) the steady advancement of the Group's projects into later stages.

Gross Profit and Its Margin

• The Group's gross profit increased by 40.6 % period-over-period to RMB 1,371.3 million, with a gross profit margin of 37.0 % for the six months ended June 30, 2026, a 0.9 percentage points increase compared to that of 2025 1H.
• This improvement is driven by (i) the continuous enhancement of our overall operation and manufacturing efficiency, (ii) the utilization ratio of production facilities continued to maintain at a high level, mainly due to strong customer demand, (iii) the successful ramp-up of operating production lines, and(iv) increased contribution from higher value-added services.

Adjusted Net profit attributable to owners of the Company and Its Margin

• The Group's adjusted net profit attributable to owners of the Company increased by 37.4% period-over-period to RMB 1,027.3 million, demonstrating the strong profit growth momentum of the Group's core operating business. The margin of adjusted net profit attributable to owners of the Company remained stable at 27.8 % for the six months ended June 30, 2026, a 0.1 percentage points increase compared to that of 2025 1H.
• This growth and improvement were primarily driven by the factors above and continuous disciplined control of SG&A expenses.

Customers and Projects Highlights for Interim Results of 2026

• We have continuously expanded our customer base, reaching a cumulative total of 814.
• The "Enable, Follow, and Win the Molecule" strategy continued to drive sustained and rapid project growth. The total number of integrated projects ("iCMC projects") is 328, with 51 newly signed integrated projects.
• The Group has successfully secured 21 PPQ projects, with 2 new PPQ projects signed in 2026 1H.
• The Group currently holds 2 commercial-stage projects, demonstrating its emerging track record and proven capabilities in commercial manufacturing.
• The Group has a diversified project base covering both innovative ADC and broader bioconjugate ("XDC") projects. The total number of integrated ADC projects reached 286, and the number of integrated XDC projects increased to 42.
• In 2026 1H, the Group explored over 3,100 molecules of multiple modalities, including bispecific ADCs, dual-payload ADCs, degrader-antibody conjugates (DAC), antibody-oligonucleotide conjugates (AOC), antibody-peptide conjugates (APC), etc. Notably, the Group explored over 22,000 ADC/XDC molecules cumulatively as at the end of the Reporting Period.

Development of Fully Integrated R&D Technology Platform During 2026 1H

The Group provides customers with innovative conjugation and payload-linker technologies to accelerate the development of next-generation bioconjugates. Multiple customer programs enabled by the WuXiDARx™, X-LinC™, and WuXi Payload-Linker™ platforms have advanced from PCC to iCMC and clinical development, demonstrating the robustness, scalability, and broad applicability of the Group's integrated technology platform.

WuXiDARx™ - Conjugation platform

WuXiDARx™ is a clinically validated conjugation platform that enables highly homogeneous ADCs, APCs, AOCs, and dual-payload ADCs, supporting diverse bioconjugate modalities from discovery through clinical development. The platform has successfully facilitated customers bringing 8 ADC pipelines from preclinical stage to clinical stage.

• WuXiDAR4™ enhances ADC homogeneity and therapeutic index (TI), enabling over 10 iCMC programs, including 8 in clinical development.
• WuXiDAR2™ delivers highly homogeneous ADCs and APCs, enabling the first DAR2 ADC program advance to iCMC-ready stage.
• WuXiDAR1™ delivers highly homogeneous DAR1 AOCs, validating the platform for AOC development.
• WuXiDARx™ technology also enables sequential, precise dual-payload conjugation via native interchain cysteine sites without antibody engineering or enzymatic conjugation, offering a streamlined, cost-effective single-platform solution. The technology has successfully enabled first dual-payload ADC program to iCMC-ready stage.

WuXi Payload-Linker™ - Payload-linker platform

WuXi Payload-Linker™ technologies enable next-generation ADCs with differentiated mechanisms of action, improved therapeutic index, and enhanced developability through proprietary payload and hydrophilic linker technologies.

• WuXiTecan-2™ is a proprietary exatecan-based payload-linker platform featuring improved hydrophilicity, plasma stability, and robust in vivo efficacy. The technology has been successfully applied to 3 iCMC-stage customer programs through technology licensing agreements with Earendil Labs and a European biotech company in 2026, demonstrating its strong developability and translational potential.  Notably, a WuXiTecan-2™- based dual-payload ADC (MMAE + WuXiTecan-2™) successfully achieved PCC and advanced into iCMC development, highlighting the platform's ability to enable next-generation ADC development.
• WuXiLinker™ is a proprietary hydrophilic linker technology that enables hydrophobic payloads with improved developability, stability, and conjugation performance. The technology has been successfully extended to multiple payloads, including WuXiMMAE™, WuXiATRi™, and WuXiEribulin™, and extended beyond established payloads to support the development of next-generation payload-linker technologies, including DDR inhibitors and other differentiated hydrophobic payloads.
• X-LinC™ is a proprietary stable conjugation connector that replaces conventional maleimide chemistry, enhancing ADC stability through reduced payload-linker deconjugation and improved in vivo stability.

Capacity Expansion & Business Operation Updates During 2026 1H

• The total number of full-time employees increased to 3,628 in the Group, driven by rapid business growth and the Group's capacity expansion. WuXi XDC's standalone headcount grew to over 3,100 employees. The Group continued to invest in talent development, sustaining a high-caliber standalone and domestic workforce, with more than 50% of employees holding master's degrees or above.
• All of the Group's manufacturing operations are conducted in accordance with the GMP regulations set by the FDA, EMA, and NMPA. The Group has completed 200+ GMP audits from global customers, including 27 audits by EU Qualified Persons.
• The acquisition of BioDlink in March 2026 increased the Group's manufacturing capacity, broadened its project portfolio, and expanded its client network.
• In August 2026, the Singapore facility's XmAb/XBCM3 achieved GMP release, marking the Group's first mAb and bioconjugates manufacturing site overseas. XDP4 is scheduled for GMP release by the end of August 2026.
• Future capacities build-out: The XDP5 and XDP6 expansions in Wuxi are designed to augment the Group's drug product manufacturing capacity, reinforcing our ability to support late-stage clinical and commercial-scale programs across diverse modalities, including ADCs, AOCs, and other novel bioconjugates. Meanwhile, XPLM2 in Jiangyin site secures vertical integration into the critical payload and linker supply chain.
• The Group was named the winner of "Best CDMO" for 3 consecutive year from 2023 to 2025, as well as "Best CRO" at the 2025 World ADC Awards.
• The Group is committed to ESG excellence, reflected in its "A" ratings from MSCI ESG (2026) and Wind ESG (2025), and its designation as an Industry ESG Leader by Morningstar Sustainalytics.

***

Key Financial Performance (For the Six Months Ended June 30)

About WuXi XDC

WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) is a leading global CRDMO focused on bioconjugate market. It provides end-to-end contract research, development and manufacturing services for ADC and broader bioconjugates. For more information about WuXi XDC, please visit: www.wuxixdc.com

Contacts

Investor: [email protected]
Media: [email protected]
BD: [email protected]

Forward-Looking Statements

This presentation may contain certain "forward-looking statements" which are not historical facts, but instead are predictions about future events based on our beliefs as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain, and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, the ability of our service offerings to compete effectively, our ability to meet timelines for the expansion of our service offerings, and our ability to protect our customers' intellectual property. Our forward-looking statements in this presentation speak only as of the date on which they are made, and we assume no obligation to update any forward-looking statements except as required by applicable law or listing rules. Accordingly, you are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section.

Use of Adjusted Financial Measures and CER (Non-IFRS Measures)

The Group defines "adjusted net profit attributable to owners of the Company" as net profit attributable to owners of the Company after elimination of share-based compensation expense as non-cash expenditure, net foreign exchange loss or gain as non-operating item, non-recurring/one-off transaction costs as non-operating item, and net of interest income and finance costs as non-operating item. We believe that the adjusted financial measures used in this presentation are useful for understanding and assessing underlying business performance and operating trends, and we believe that management and investors may benefit from referring to these adjusted financial measures in assessing our financial performance by eliminating the impact of certain unusual and non-recurring items that we do not consider indicative of the performance of our business. However, the presentation of these non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies. The Company's functional currency is Renminbi ("RMB"). Given that a majority of the Group's service contracts are denominated in U.S. dollars ("USD"), the Group presents certain operating results on both an actual exchange rate ("AER") basis and a constant exchange rate ("CER") basis.

• Cash position^[i] was RMB40.48 billion (US$5.97 billion) as of June 30, 2026
• Quarterly total revenues were RMB19.74 billion, a 51.5% increase quarter-over-quarter
• Quarterly gross margin was 20.7%, an increase of 3.4 percentage points over the same period of 2025
• Quarterly vehicle margin was 12.1%, remained relatively stable quarter-over-quarter

GUANGZHOU, China, Aug. 24, 2026 /PRNewswire/ -- XPeng Inc. ("XPENG" or the "Company," NYSE: XPEV and HKEX: 9868), a leading global Physical AI company, today announced its unaudited financial results for the three months ended June 30, 2026.

Operational and Financial Highlights for the Three Months Ended June 30, 2026

• Total deliveries of vehicles were 103,295 for the second quarter of 2026, representing an increase of 0.1% from 103,181 in the corresponding period of 2025.
  
  
• XPENG's physical sales network had a total of 740 stores, covering 257 cities as of June 30, 2026.
  
  
• XPENG self-operated charging station network reached 3,780 stations, including 2,720 XPENG ultra-fast charging stations as of June 30, 2026.
  
  
• Total revenues were RMB19.74 billion (US$2.91 billion) for the second quarter of 2026, representing an increase of 8.0% from the same period of 2025, and an increase of 51.5% from the first quarter of 2026.
  
  
• Revenues from vehicle sales were RMB17.05 billion (US$2.51 billion) for the second quarter of 2026, representing an increase of 1.0% from the same period of 2025, and an increase of 55.0% from the first quarter of 2026.
  
  
• Gross margin was 20.7% for the second quarter of 2026, compared with 17.3% for the same period of 2025 and 20.6% for the first quarter of 2026.
  
  
• Vehicle margin, which is gross profit of vehicle sales as a percentage of vehicle sales revenue, was 12.1% for the second quarter of 2026, compared with 14.3% for the same period of 2025 and 12.1% for the first quarter of 2026.
  
  
• Net loss was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026. Excluding share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, non-GAAP net loss was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.
  
  
• Net loss attributable to ordinary shareholders of XPENG was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026. Excluding share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, non-GAAP net loss attributable to ordinary shareholders of XPENG was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.
  
  
• Basic and diluted net loss per American depositary share (ADS) were both RMB1.40 (US$0.21) and basic and diluted net loss per ordinary share were both RMB0.70 (US$0.10) for the second quarter of 2026. Each ADS represents two Class A ordinary shares.
  
  
• Non-GAAP basic and diluted net loss per ADS were both RMB1.29 (US$0.19), and non-GAAP basic and diluted net loss per ordinary share were both RMB0.65 (US$0.10) for the second quarter of 2026.
  
  
• Cash position was RMB40.48 billion (US$5.97 billion) as of June 30, 2026, compared with RMB42.09 billion as of March 31, 2026.

Management Commentary

"The back-to-back success of the GX and MONA L03 gives us greater confidence in our upcoming new models, as we translate our leading edge in smart technologies and design into more blockbuster products and stronger brand momentum," said Mr. Xiaopeng He, Chairman and CEO of XPENG. "The development of the mass-production version of XPENG's humanoid robot has recently reached several significant milestones. I believe XPENG will not only build one of China's most valuable humanoid robotics companies, but also become a global leader in physical AI, spearheading the large-scale adoption and commercialization of advanced general-purpose humanoid robots and autonomous driving technologies in China and overseas."

"During the second quarter of 2026, our operations remained resilient despite industry-wide cost pressures. Driven by breakthroughs in our premiumization and globalization efforts, our gross margin continued to exceed 20%," added Dr. Hongdi Brian Gu, Vice Chairman and Co-President of XPENG. "I expect the mass production and commercialization of physical AI technologies to accelerate over the coming year, generating meaningful gross profit growth to support our continued R&D investment in physical AI."

Recent Developments

Deliveries in July 2026

• Total deliveries were 38,027 vehicles in July 2026.
  
  
• As of July 31, 2026, year-to-date total deliveries were 204,004 vehicles.

Launch of MONA L03

On July 16, 2026, XPENG held the global launch event of MONA L03, the Next-Gen AI SUV Coupe, in Munich, Germany.

Entering into the Dogotix Share Purchase Agreement

On August 24, 2026, Dogotix Inc. (a subsidiary of the Company) entered into a share purchase agreement (the "Dogotix Share Purchase Agreement") with, among others, certain subscribers, pursuant to which such subscribers conditionally agreed to subscribe for certain shares to be newly issued by Dogotix Inc. at an aggregate purchase price of US$900 million. For details, please refer to the announcement of the Company dated August 24, 2026, in relation to, among others, the Dogotix Share Purchase Agreement.

Unaudited Financial Results for the Three Months Ended June 30, 2026

Total revenues were RMB19.74 billion (US$2.91 billion) for the second quarter of 2026, representing an increase of 8.0% from RMB18.27 billion for the same period of 2025 and an increase of 51.5% from RMB13.03 billion for the first quarter of 2026.

Revenues from vehicle sales were RMB17.05 billion (US$2.51 billion) for the second quarter of 2026, representing an increase of 1.0% from RMB16.88 billion for the same period of 2025, and an increase of 55.0% from RMB11.00 billion for the first quarter of 2026. The quarter-over-quarter increase was mainly attributable to higher vehicle deliveries.

Revenues from services and others were RMB2.70 billion (US$0.40 billion) for the second quarter of 2026, representing an increase of 93.9% from RMB1.39 billion for the same period of 2025 and an increase of 32.6% from RMB2.03 billion for the first quarter of 2026. The year-over-year and quarter-over-quarter increases were primarily attributable to increased revenues from (i) technical research and development services ("technical R&D services") rendered to a car manufacturer (the "Manufacturer") with the successful achievement of certain key milestones in the current period, under the agreement entered into with the Manufacturer; and (ii) parts and accessories sales.

Cost of sales was RMB15.66 billion (US$2.31 billion) for the second quarter of 2026, representing an increase of 3.7% from RMB15.11 billion for the same period of 2025 and an increase of 51.3% from RMB10.35 billion for the first quarter of 2026. The quarter-over-quarter increase was mainly in line with vehicle deliveries as described above.

Gross margin was 20.7% for the second quarter of 2026, compared with 17.3% for the same period of 2025 and 20.6% for the first quarter of 2026.

Vehicle margin was 12.1% for the second quarter of 2026, compared with 14.3% for the same period of 2025 and 12.1% for the first quarter of 2026. The year-over-year decrease was due to product generation transition.

Services and others margin was 75.1% for the second quarter of 2026, compared with 53.6% for the same period of 2025 and 66.5% for the first quarter of 2026. The year-over-year and quarter-over-quarter increases were attributable to the aforementioned revenue from technical R&D services and parts and accessories sales.

Research and development expenses were RMB2.91 billion (US$0.43 billion) for the second quarter of 2026, representing an increase of 32.1% from RMB2.21 billion for the same period of 2025 and an increase of 0.3% from RMB2.91 billion for the first quarter of 2026. The year-over-year increase was mainly due to higher expenses related to the development of new vehicle models and AI-related technologies as the Company expanded its product portfolio to support future growth.

Selling, general and administrative expenses were RMB2.50 billion (US$0.37 billion) for the second quarter of 2026, representing an increase of 15.2% from RMB2.17 billion for the same period of 2025 and an increase of 32.5% from RMB1.88 billion for the first quarter of 2026. The year-over-year increase was primarily due to higher marketing and advertising expenses. The quarter-over-quarter increase was primarily due to the higher commission to the franchised stores and higher marketing and advertising expenses.

Other income, net was RMB0.14 billion (US$0.02 billion) for the second quarter of 2026, representing a decrease of 42.2% from RMB0.24 billion for the same period of 2025 and a decrease of 24.7% from RMB0.18 billion for the first quarter of 2026. The year-over-year and quarter-over-quarter decreases were primarily due to the decrease in receipt of government subsidies.

Fair value gain on derivative liability relating to the contingent consideration was a gain of RMB0.05 billion (US$0.01 billion) for the second quarter of 2026, compared with a gain of RMB0.03 billion for the same period of 2025 and a gain of RMB0.05 billion for the first quarter of 2026. This non-cash gain resulted from the fair value change of the contingent consideration related to the acquisition of DiDi Global Inc. ("DiDi")'s smart auto business.

Loss from operations was RMB1.14 billion (US$0.17 billion) for the second quarter of 2026, compared with RMB0.93 billion for the same period of 2025 and RMB1.87 billion for the first quarter of 2026.

Non-GAAP loss from operations, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.04 billion (US$0.15 billion) for the second quarter of 2026, compared with a loss of RMB0.84 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Net loss was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Non-GAAP net loss, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.

Net loss attributable to ordinary shareholders of XPENG was RMB1.34 billion (US$0.20 billion) for the second quarter of 2026, compared with a loss of RMB0.48 billion for the same period of 2025 and a loss of RMB1.78 billion for the first quarter of 2026.

Non-GAAP net loss attributable to ordinary shareholders of XPENG, which excludes share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, was RMB1.24 billion (US$0.18 billion) for the second quarter of 2026, compared with a loss of RMB0.39 billion for the same period of 2025 and a loss of RMB1.69 billion for the first quarter of 2026.

Basic and diluted net loss per ADS were both RMB1.40 (US$0.21) for the second quarter of 2026, compared with RMB0.50 basic and diluted net loss per ADS for the second quarter of 2025 and RMB1.87 basic and diluted net loss per ADS for the first quarter of 2026.

Non-GAAP basic and diluted net loss per ADS were both RMB1.29 (US$0.19) for the second quarter of 2026, compared with RMB0.41 non-GAAP basic and diluted net loss per ADS for the second quarter of 2025 and RMB1.76 non-GAAP basic and diluted net loss per ADS for the first quarter of 2026.

Balance Sheets

As of June 30, 2026, the Company had a cash position of RMB40.48 billion (US$5.97 billion), compared with RMB42.09 billion as of March 31, 2026.

Business Outlook

For the third quarter of 2026, the Company expects:

• Deliveries of vehicles to be between 115,000 and 121,000, representing a year-over-year change of approximately -0.87% to +4.30%, and a quarter-over-quarter increase of approximately 11.33% to 17.14%.
  
  
• Total revenues to be between RMB21.7 billion and RMB23.4 billion, representing a year-over-year increase of approximately 6.47% to 14.81%, and a quarter-over-quarter increase of approximately 9.91% to 18.52%.

The above outlook is based on the current market conditions and reflects the Company's preliminary estimates of market and operating conditions, and customer demand, which are all subject to change.

Conference Call

The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on August 24, 2026 (8:00 PM Beijing/Hong Kong Time on August 24, 2026).

For participants who wish to join the call by phone, please access the link provided below to complete the pre-registration process and dial in 5 minutes prior to the scheduled call start time. Upon registration, each participant will receive dial-in details to join the conference call.

Event Title:                XPENG Second Quarter 2026 Earnings Conference Call
Pre-registration link:  https://s1.c-conf.com/diamondpass/10056093-aweri7.html

Additionally, a live and archived webcast of the conference call will be available on the Company's investor relations website at http://ir.xiaopeng.com.

A replay of the conference call will be accessible approximately an hour after the conclusion of the call until September 1, 2026, by dialing the following telephone numbers:

About XPENG

XPENG is a leading global Physical AI company, dedicated to bringing artificial intelligence into the physical world to reshape future mobility and smart living. Through in-house R&D, XPENG has developed a full-stack Physical AI architecture spanning Turing AI chips, world foundation models, and highly integrated software and hardware applications. This unified technology foundation of XPENG powers an expansive product portfolio of smart EVs, robotaxis, and humanoid robots, advancing the deployment of Physical AI at scale. Headquartered in Guangzhou, China, XPENG is dual-primary listed on the New York Stock Exchange and the Hong Kong Stock Exchange. With global capabilities across R&D, manufacturing, sales, and services, XPENG drives continuous technological innovation and fosters an open Physical AI ecosystem, making life smarter, safer, and better for users worldwide. For more information, please visit https://www.xpeng.com/.

Use of Non-GAAP Financial Measures

The Company uses non-GAAP measures, such as non-GAAP loss from operations, non-GAAP net loss, non-GAAP net loss attributable to ordinary shareholders, non-GAAP basic loss per ordinary share and non-GAAP basic loss per ADS, in evaluating its operating results and for financial and operational decision-making purposes. By excluding the impact of share-based compensation expenses and fair value gain on derivative liability relating to the contingent consideration, the Company believes that the non-GAAP financial measures help identify underlying trends in its business and enhance the overall understanding of the Company's past performance and future prospects. The Company also believes that the non-GAAP financial measures allow for greater visibility with respect to key metrics used by the Company's management in its financial and operational decision-making. The non-GAAP financial measures are not presented in accordance with U.S. GAAP and may be different from non-GAAP methods of accounting and reporting used by other companies. The non-GAAP financial measures have limitations as analytical tools and when assessing the Company's operating performance, investors should not consider them in isolation, or as a substitute for net loss or other consolidated statements of comprehensive loss data prepared in accordance with U.S. GAAP. The Company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure. The Company mitigates these limitations by reconciling the non-GAAP financial measures to the most comparable U.S. GAAP performance measures, all of which should be considered when evaluating the Company's performance.

For more information on the non-GAAP financial measures, please see the table captioned "Unaudited Reconciliations of GAAP and non-GAAP Results" set forth in this announcement.

Exchange Rate Information

This announcement contains translations of certain RMB amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB are made at a rate of RMB6.79 to US$1.00, the exchange rate on June 30, 2026, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the RMB or U.S. dollar amounts referred to could be converted into U.S. dollars or RMB, as the case may be, at any particular rate or at all.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Statements that are not historical facts, including statements about XPENG's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: XPENG's goal and strategies; XPENG's expansion plans; XPENG's future business development, financial condition and results of operations; the trends in, and size of, China's EV market; XPENG's expectations regarding demand for, and market acceptance of, its products and services; XPENG's expectations regarding its relationships with customers, suppliers, third-party service providers, strategic partners and other stakeholders; general economic and business conditions; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in XPENG's filings with the United States Securities and Exchange Commission. All information provided in this announcement is as of the date of this announcement, and XPENG does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

For Investor Enquiries
IR Department
XPeng Inc.
E-mail: [email protected]

Jenny Cai
Piacente Financial Communications
Tel: +1-212-481-2050 or +86-10-6508-0677
E-mail: [email protected]

For Media Enquiries
PR Department
XPeng Inc.
E-mail: [email protected]